TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10851109

Group type: EXPERIMENTAL
Intervention: Nimesulide (100 mg twice daily for 10 days)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Ibuprofen (600 mg three times daily for 10 days)
Number of subjects: 104
Study: 9507415

Group type: EXPERIMENTAL
Intervention: No treatment (idiopathic cases)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Metastatic disease at the base of the skull
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Chiari malformation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dural arteriovenous fistula of the transverse sinus
Number of subjects: 9
Study: 7810816

Group type: EXPERIMENTAL
Intervention: Praziquantel 40 mg/kg as a single oral dose
Number of subjects: 40
Study: 2467132

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg single oral dose
Number of subjects: 16
Study: 29198820

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin plus resveratrol (AX + RV)
Number of subjects: 647

Group type: COMPARATOR
Intervention: Oral amoxicillin plus placebo (AX + placebo)
Number of subjects: 647
Study: 28743659

Group type: EXPERIMENTAL
Intervention: Reflexology intervention (four weekly sessions, caregiver-delivered, 30-minute protocol)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Reflexology intervention
Number of subjects: 256
Study: 26367865

Group type: EXPERIMENTAL
Intervention: Ibudilast 40 mg twice daily for 8 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 23187429

Group type: EXPERIMENTAL
Intervention: Skin traction
Number of subjects: 81

Group type: COMPARATOR
Intervention: Bed rest (no traction)
Number of subjects: 81
Study: 21971895

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Interferential current
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study: 18420431

Group type: EXPERIMENTAL
Intervention: 4% articaine (A200)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.5% bupivacaine (B200)
Number of subjects: 50
Study: 16509026

Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Nesiritide and dobutamine
Number of subjects: 1000
Study: 12699517

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg(‐1) and lidocaine 1.5 mg kg(‐1)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Rocuronium 0.6 mg kg(‐1)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Succinylcholine
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Rocuronium-lidocaine
Number of subjects: 125
Study: 15529572

Group type: EXPERIMENTAL
Intervention: Climen (estrogens and cyproteronate)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Progynova (estrogens)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 121
Study: 9558630

Group type: EXPERIMENTAL
Intervention: Otoacoustic emission testing in miners exposed to noise
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (nonexposed to noise)
Number of subjects: 74
Study: 11271285

Group type: EXPERIMENTAL
Intervention: Histidine‐Tryptophane‐Ketoglutarate (HTK) solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: University of Wisconsin (UW) solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Euro‐Collins (EC) solution
Number of subjects: 0
Study: 2853765

Group type: EXPERIMENTAL
Intervention: Lisinopril (20‐80 mg/day)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Atenolol (50‐200 mg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 31081651

Group type: EXPERIMENTAL
Intervention: WebMOVE (web-based weight-management intervention)
Number of subjects: 277

Group type: COMPARATOR
Intervention: MOVE-SMI (in-person weight-management intervention)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Both WebMOVE and MOVE-SMI
Number of subjects: 277
Study: 27227791

Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC) session (30 seconds at -60° C, 120 seconds at -135° C)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (Con) - remained seated indoors at ∼25° C
Number of subjects: 14
Study: 25695081

Group type: EXPERIMENTAL
Intervention: Phase I procedures (soft tissue surgery)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Phase II procedures (orthognathic surgery)
Number of subjects: 46

Group type: COMPARATOR
Intervention: No surgery patients (control group)
Number of subjects: 46
Study: 23747044

Group type: EXPERIMENTAL
Intervention: Clopidogrel treatment with high residual platelet reactivity (RPR) diagnosed on P2Y₁₂ reaction units >230
Number of subjects: 833

Group type: COMPARATOR
Intervention: Good responders to clopidogrel treatment
Number of subjects: 833
Study: 21968457

Group type: EXPERIMENTAL
Intervention: 6-month psychotherapy intervention
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 52
Study: 18682875

Group type: EXPERIMENTAL
Intervention: Burch surgery
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Fascial sling
Number of subjects: 655

Group type: COMPARATOR
Intervention: Control group (unsuccessful surgery)
Number of subjects: 655
Study: 17144551

Group type: EXPERIMENTAL
Intervention: Bicycle exercise in the free load regimen
Number of subjects: 0
Study: 12759268

Group type: EXPERIMENTAL
Intervention: SP/AP area curve ratio
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: SP/AP amplitude ratio
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (normal SP/AP ratios)
Number of subjects: 8
Study: 11107088

Group type: EXPERIMENTAL
Intervention: Venous cuff at the venous anastomosis
Number of subjects: 120

Group type: COMPARATOR
Intervention: No venous cuff
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Venous cuff
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Initial anastomosing vein diameter < 4 mm
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Initial anastomosing vein diameter ≥ 4 mm
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Local conditions (edema, skin atrophy, obesity)
Number of subjects: 120
Study: 8937802

Group type: EXPERIMENTAL
Intervention: Micro Plus Spirometer (MP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitalograph bellow spirometer (V)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wright PEF meter (W)
Number of subjects: 0
Study: 1556953

Group type: EXPERIMENTAL
Intervention: Exercise without calorie restriction
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Calorie restriction without exercise
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control
Number of subjects: 3
Study: 3883167

Group type: EXPERIMENTAL
Intervention: Segmental mastectomy plus radiation
Number of subjects: 1843

Group type: COMPARATOR
Intervention: Segmental mastectomy alone
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: Segmental mastectomy with radiation
Number of subjects: 1843

Group type: COMPARATOR
Intervention: Segmental mastectomy without radiation
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: Segmental mastectomy with radiation among patients with positive nodes
Number of subjects: 1843

Group type: COMPARATOR
Intervention: Segmental mastectomy without radiation among patients with positive nodes
Number of subjects: 1843
Study: 30633139

Group type: EXPERIMENTAL
Intervention: Riboflavin 400 mg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 29257143

Group type: EXPERIMENTAL
Intervention: Interferential electrical stimulation plus pelvic floor muscle exercises
Number of subjects: 90

Group type: COMPARATOR
Intervention: Pelvic floor muscle exercises plus sham stimulation
Number of subjects: 90
Study: 26461929

Group type: EXPERIMENTAL
Intervention: Initial cervical length (CL) ≥39 mm
Number of subjects: 786

Group type: COMPARATOR
Intervention: Initial cervical length (CL) <39 mm
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Initial cervical length (CL) <25 mm or SPTB before follow-up CL
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Initial cervical length (CL) ≥25 mm
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Receiver operator characteristics curve
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Initial cervical length cutoffs
Number of subjects: 786
Study: 24905030

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg robatumumab followed by 10 mg/kg biweekly in P2
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 10 mg/kg robatumumab in P2
Number of subjects: 41

Group type: COMPARATOR
Intervention: 0.3 mg/kg robatumumab
Number of subjects: 41
Study: 21937177

Group type: EXPERIMENTAL
Intervention: CT/US fusion imaging during pRFA (group 1)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: CT/US fusion imaging during pRFA (group 2)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: CT/US fusion imaging during pRFA (group 3)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: CT/US fusion imaging
Number of subjects: 37
Study: 20444534

Group type: EXPERIMENTAL
Intervention: Dienogest 2mg
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 17712070

Group type: EXPERIMENTAL
Intervention: On-demand relaparotomy strategy
Number of subjects: 232

Group type: COMPARATOR
Intervention: Planned relaparotomy strategy
Number of subjects: 232
Study: 15642557

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study: 12396296

Group type: EXPERIMENTAL
Intervention: Liquid Gaviscon (20 mL)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Gaviscon Advance (10 mL)
Number of subjects: 6
Study: 9932999

Group type: EXPERIMENTAL
Intervention: Diode laser peripheral retinal photocoagulation
Number of subjects: 103
Study: 8675854

Group type: EXPERIMENTAL
Intervention: Spontaneous pushing
Number of subjects: 32

Group type: COMPARATOR
Intervention: Directed pushing
Number of subjects: 32
Study: 2114036

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 500 mg/kg
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo (albumin-saline)
Number of subjects: 500
Study: 7284972

Group type: EXPERIMENTAL
Intervention: Weekly oral 5-fluorouracil (5-FU)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Weekly intravenous 5-fluorouracil (5-FU)
Number of subjects: 51
Study: 30599367

Group type: EXPERIMENTAL
Intervention: Home-delivered attention bias modification (HD-ABM) training
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 82

Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 82
Study: 27442139

Group type: EXPERIMENTAL
Intervention: Diagram-assisted interview (diagram-first condition)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Conventional interview (conventional-first condition)
Number of subjects: 287
Study: 24243484

Group type: EXPERIMENTAL
Intervention: VADSS
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control
Number of subjects: 31
Study: 23974035

Group type: EXPERIMENTAL
Intervention: Weight loss only treatment (WL)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AT) + weight loss (WL)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RT) + weight loss (WL)
Number of subjects: 252
Study: 21329622

Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide tablets
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide capsules
Number of subjects: 302
Study: 19433701

Group type: EXPERIMENTAL
Intervention: Exposure to small branded promotional items for Lipitor (atorvastatin)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Control group (no exposure to promotional items)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: University of Miami students
Number of subjects: 352

Group type: COMPARATOR
Intervention: University of Pennsylvania students
Number of subjects: 352
Study: 16724678

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) at a dose of 2400 mg/day for 12 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 20
Study: 15019882

Group type: EXPERIMENTAL
Intervention: Routine functional testing
Number of subjects: 348

Group type: COMPARATOR
Intervention: Selective functional testing
Number of subjects: 348
Study: 11357851

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (enoxaparin)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Dextran 70
Number of subjects: 314
Study: 9143868

Group type: EXPERIMENTAL
Intervention: Controlled diffusion diltiazem (180 mg taken in the morning)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Conventional release diltiazem (90 mg taken twice daily)
Number of subjects: 7
Study: 7956413

Group type: EXPERIMENTAL
Intervention: Metaproterenol (1 mL 0.5% in 3 mL saline solution)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline solution (4 mL)
Number of subjects: 8
Study: 3238472

Group type: EXPERIMENTAL
Intervention: Full-dose HB vaccine (Group A, 69 infants)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Half-dose HB vaccine (Group B, 70 infants)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Untreated control group (Group C, 65 infants)
Number of subjects: 204
Study: 29560766

Group type: EXPERIMENTAL
Intervention: Blunt fascial opening
Number of subjects: 123

Group type: COMPARATOR
Intervention: Sharp fascial opening
Number of subjects: 123
Study: 27208498

Group type: EXPERIMENTAL
Intervention: 2 mg brexpiprazole + ADT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3 mg brexpiprazole + ADT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 mg brexpiprazole + ADT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo + ADT
Number of subjects: 0
Study: 24293166

Group type: EXPERIMENTAL
Intervention: Cryoballoon
Number of subjects: 110

Group type: COMPARATOR
Intervention: Open‐irrigated tip RF catheter
Number of subjects: 110

Group type: COMPARATOR
Intervention: Visually guided laser balloon
Number of subjects: 110

Group type: COMPARATOR
Intervention: Open‐irrigated tip RF catheter with contact‐force‐sensing technology
Number of subjects: 110
Study: 23758673

Group type: EXPERIMENTAL
Intervention: Kivia powder (5.5 g daily for four weeks)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 20010135

Group type: EXPERIMENTAL
Intervention: Community-based aquatic exercise program (n = 125)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Usual activity levels (Control group, n = 124)
Number of subjects: 249
Study: 18164276

Group type: EXPERIMENTAL
Intervention: Feature-Positive Effect (FPE) test
Number of subjects: 53
Study: 17312823

Group type: EXPERIMENTAL
Intervention: MCCU (mobile coronary care unit) group
Number of subjects: 248

Group type: COMPARATOR
Intervention: Hospital group
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: MCCU group
Number of subjects: 248
Study: 12939876

Group type: EXPERIMENTAL
Intervention: Fenazid (0.5 g daily for 2 months)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Routine antituberculous chemotherapy regimen including isoniazid
Number of subjects: 49
Study: 10617523

Group type: EXPERIMENTAL
Intervention: Problem solving treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of problem solving treatment and antidepressant medication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Problem solving treatment delivered by practice nurses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Problem solving treatment delivered by general practitioners
Number of subjects: 0
Study: 9169747

Group type: EXPERIMENTAL
Intervention: Whole-cell pertussis vaccine (wP)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine (aP-SB)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine (aP-CB)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group (DT or unresponsive pertussis vaccine recipients)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Prevaccination children
Number of subjects: 5
Study: 8466237

Group type: EXPERIMENTAL
Intervention: 2 mg nebulised budesonide
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 36
Study: 3512507

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (methicillin 2 g and netilmicin 200 mg, three doses)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 29328860

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 1918

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1918
Study: 27681077

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (daily capsule containing Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum at 2×10^9 CFU/g each plus 800 mg inulin) for 6 weeks
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 24947504

Group type: EXPERIMENTAL
Intervention: Low dose of chlorogenic acids (412 μmol)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Medium dose of chlorogenic acids (635 μmol)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High dose of chlorogenic acids (795 μmol)
Number of subjects: 11
Study: 22544046

Group type: EXPERIMENTAL
Intervention: Cyproheptadine 4 mg three times per day for 12 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 20573567

Group type: EXPERIMENTAL
Intervention: Ephedra dry extract (1g once per day for 14 days)
Number of subjects: 20
Study: 18208639

Group type: EXPERIMENTAL
Intervention: Exposure to mortality-related information about the risks of binge drinking (Study 2)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Exposure to information about the mortality-related risks of binge drinking (Study 1)
Number of subjects: 393
Study: 15855489

Group type: EXPERIMENTAL
Intervention: 200 mg infusion of isoniazid
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 100 mg oral single dose of isoniazid
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 300 mg oral single dose of isoniazid
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: NAT2 genotype assessment
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Analysis of variance
Number of subjects: 18
Study: 11943795

Group type: EXPERIMENTAL
Intervention: Community based screening programme for melanoma (3 years duration)
Number of subjects: 560000

Group type: COMPARATOR
Intervention: Normal practice (control group)
Number of subjects: 560000
Study: 10606106

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Stress-induced reversible thallium defects (both PTCA and CABG)
Number of subjects: 336
Study: 8524425

Group type: EXPERIMENTAL
Intervention: Sucralfate suspension 2 g daily (twice daily for 6 months)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo (twice daily for 6 months)
Number of subjects: 184
Study: 1771280

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 31

Group type: COMPARATOR
Intervention: Thiopentone-Isoflurane
Number of subjects: 31
Study: 7048519

Group type: EXPERIMENTAL
Intervention: Cephalosporin (oral)
Number of subjects: 20
Study: 30507832

Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) headset with live holographic orientation feedback
Number of subjects: 24

Group type: COMPARATOR
Intervention: Hands-on training by an expert surgeon
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) headset
Number of subjects: 24
Study: 29384023

Group type: EXPERIMENTAL
Intervention: ProFiL program
Number of subjects: 442

Group type: COMPARATOR
Intervention: Usual care (UC) group
Number of subjects: 442
Study: 27206939

Group type: COMPARATOR
Intervention: Evacetrapib 500 mg/d
Number of subjects: 393

Group type: COMPARATOR
Intervention: Evacetrapib plus statins (100 mg evacetrapib + simvastatin 40 mg/d, atorvastatin 20 mg/d, or rosuvastatin 10 mg/d)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Evacetrapib plus statins
Number of subjects: 393

Group type: COMPARATOR
Intervention: Evacetrapib alone or with statins
Number of subjects: 393
Study: 25052061

Group type: EXPERIMENTAL
Intervention: MEmory Specificity Training (MEST)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Education and Support (ES)
Number of subjects: 60
Study: 22271078

Group type: EXPERIMENTAL
Intervention: IVC filter
Number of subjects: 141

Group type: COMPARATOR
Intervention: No filter (control group)
Number of subjects: 141
Study: 19131401

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg daily
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 17553812

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg/day)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam/amoxicillin-clavulanate
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 78
Study: 15208125

Group type: EXPERIMENTAL
Intervention: iodixanol
Number of subjects: 200

Group type: COMPARATOR
Intervention: iohexol
Number of subjects: 200
Study: 12701645

Group type: EXPERIMENTAL
Intervention: Fluticasone Diskhaler (Flutide)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Beclomethasone (BDI)
Number of subjects: 246
Study: 9715790

Group type: EXPERIMENTAL
Intervention: Intranasal ANG II (400 microg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous ANG II (2.5 microg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7866465

Group type: EXPERIMENTAL
Intervention: 4.2 MJ/d diet with exercise
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 4.2 MJ/d diet
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 118
Study: 2555803

Group type: EXPERIMENTAL
Intervention: Oxycodone (0.13 mg/kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (100 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 782808

Group type: EXPERIMENTAL
Intervention: Sisomicin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 12
Study: 31446629

Group type: EXPERIMENTAL
Intervention: Sugar consumption restricted to less than 3% of total daily calories for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual diet (control group)
Number of subjects: 0